Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 38% phase transition success rate ... colorectal cancer and adenocarcinoma of the prostate, cervical cancer, HPV16 positive ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase I for Epithelial Ovarian Cancer.

Clear cell RCC accounts for approximately 75% of cases while the remaining non-clear ... They noted that these rates are comparable to those of ovarian cancer and pancreatic cancer, which already have ...